Literature DB >> 23785176

Substrate-dependent inhibition of human MATE1 by cationic ionic liquids.

Lucy J Martínez-Guerrero1, Stephen H Wright.   

Abstract

The multidrug and toxin extruders 1- and 2-K (MATE1 and MATE2-K) are expressed in the luminal membrane of renal proximal tubule cells and provide the active step in the secretion of molecules that carry a net positive charge at physiologic pH, so-called organic cations. The present study tested whether structurally distinct MATE substrates can display different quantitative profiles of inhibition when interacting with structurally distinct ligands. The tested ligands were three structurally similar cationic ionic liquids (ILs, salts in the liquid state: N-butylpyridinium, NBuPy; 1-methyl-3-butylimidazolium, Bmim; and N-butyl-N-methylpyrrolidinium, BmPy). Uptake was measured using Chinese hamster ovary cells that stably expressed MATE1 or MATE2-K. By trans-stimulation, all three ILs were transported by both MATE transporters. The three ILs also inhibited uptake of three structurally distinct MATE substrates: 1-methyl-4-phenylpyridinium (MPP), triethylmethylammonium (TEMA), and N,N,N-trimethyl-2-[methyl(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)amino]ethanaminium (NBD-MTMA). MATE1 displayed a higher affinity for the pyridinium-based NBuPy (IC50 values, 2-4 µM) than for either the pyrrolidinium- (BmPy; 20-70 µM) or imidazolium-based ILs (Bmim; 15-60 µM). Inhibition of MPP, TEMA, and NBD-MTMA transport by NBuPy was competitive, with comparable Ki values against all substrates. Bmim also competitively blocked the three substrates but with Ki values that differed significantly (20 µM against MPP and 30 µM against NBD-MTMA versus 60 µM against TEMA). Together, these data indicate that renal secretion of ILs by the human kidney involves MATE transporters and suggest that the mechanism of transport inhibition is ligand-dependent, supporting the hypothesis that the binding of substrates to MATE transporters involves interaction with a binding surface with multiple binding sites.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23785176      PMCID: PMC3876781          DOI: 10.1124/jpet.113.204206

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  37 in total

1.  A human transporter protein that mediates the final excretion step for toxic organic cations.

Authors:  Masato Otsuka; Takuya Matsumoto; Riyo Morimoto; Shigeo Arioka; Hiroshi Omote; Yoshinori Moriyama
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-05       Impact factor: 11.205

Review 2.  The role of transporters in drug interactions.

Authors:  Christopher J Endres; Peng Hsiao; Francisco S Chung; Jashvant D Unadkat
Journal:  Eur J Pharm Sci       Date:  2005-12-20       Impact factor: 4.384

3.  Transport of paraquat by human organic cation transporters and multidrug and toxic compound extrusion family.

Authors:  Ying Chen; Shuzhong Zhang; Marco Sorani; Kathleen M Giacomini
Journal:  J Pharmacol Exp Ther       Date:  2007-05-10       Impact factor: 4.030

Review 4.  Physiological and pharmacokinetic roles of H+/organic cation antiporters (MATE/SLC47A).

Authors:  Tomohiro Terada; Ken-ichi Inui
Journal:  Biochem Pharmacol       Date:  2007-12-27       Impact factor: 5.858

5.  Identification and functional characterization of a new human kidney-specific H+/organic cation antiporter, kidney-specific multidrug and toxin extrusion 2.

Authors:  Satohiro Masuda; Tomohiro Terada; Atsushi Yonezawa; Yuko Tanihara; Koshiro Kishimoto; Toshiya Katsura; Osamu Ogawa; Ken-ichi Inui
Journal:  J Am Soc Nephrol       Date:  2006-06-28       Impact factor: 10.121

6.  Oppositely directed H+ gradient functions as a driving force of rat H+/organic cation antiporter MATE1.

Authors:  Masahiro Tsuda; Tomohiro Terada; Jun-ichi Asaka; Miki Ueba; Toshiya Katsura; Ken-ichi Inui
Journal:  Am J Physiol Renal Physiol       Date:  2006-10-17

7.  Molecular identification and functional characterization of rat multidrug and toxin extrusion type transporter 1 as an organic cation/H+ antiporter in the kidney.

Authors:  Kin-Ya Ohta; Katsuhisa Inoue; Yayoi Hayashi; Hiroaki Yuasa
Journal:  Drug Metab Dispos       Date:  2006-08-23       Impact factor: 3.922

8.  Tissue distribution, ontogeny and induction of the transporters Multidrug and toxin extrusion (MATE) 1 and MATE2 mRNA expression levels in mice.

Authors:  Andrew J Lickteig; Xingguo Cheng; Lisa M Augustine; Curtis D Klaassen; Nathan J Cherrington
Journal:  Life Sci       Date:  2008-05-18       Impact factor: 5.037

9.  The effects of dose and route on the toxicokinetics and disposition of 1-butyl-3-methylimidazolium chloride in male F-344 rats and female B6C3F1 mice.

Authors:  I G Sipes; G A Knudsen; R K Kuester
Journal:  Drug Metab Dispos       Date:  2007-10-29       Impact factor: 3.922

10.  Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters.

Authors:  Yuko Tanihara; Satohiro Masuda; Tomoko Sato; Toshiya Katsura; Osamu Ogawa; Ken-Ichi Inui
Journal:  Biochem Pharmacol       Date:  2007-04-13       Impact factor: 5.858

View more
  13 in total

1.  Common drugs inhibit human organic cation transporter 1 (OCT1)-mediated neurotransmitter uptake.

Authors:  Kelli H Boxberger; Bruno Hagenbuch; Jed N Lampe
Journal:  Drug Metab Dispos       Date:  2014-03-31       Impact factor: 3.922

2.  Lack of Influence of Substrate on Ligand Interaction with the Human Multidrug and Toxin Extruder, MATE1.

Authors:  Lucy J Martínez-Guerrero; Mark Morales; Sean Ekins; Stephen H Wright
Journal:  Mol Pharmacol       Date:  2016-07-14       Impact factor: 4.436

3.  Ligand-dependent modulation of hOCT1 transport reveals discrete ligand binding sites within the substrate translocation channel.

Authors:  Kelli H Boxberger; Bruno Hagenbuch; Jed N Lampe
Journal:  Biochem Pharmacol       Date:  2018-08-20       Impact factor: 5.858

4.  Physiologically Based Pharmacokinetic (PBPK) Modeling of Pitavastatin and Atorvastatin to Predict Drug-Drug Interactions (DDIs).

Authors:  Peng Duan; Ping Zhao; Lei Zhang
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-08       Impact factor: 2.441

Review 5.  Molecular Modeling of Drug-Transporter Interactions-An International Transporter Consortium Perspective.

Authors:  Avner Schlessinger; Matthew A Welch; Herman van Vlijmen; Ken Korzekwa; Peter W Swaan; Pär Matsson
Journal:  Clin Pharmacol Ther       Date:  2018-08-30       Impact factor: 6.875

6.  Impact of Substrate-Dependent Inhibition on Renal Organic Cation Transporters hOCT2 and hMATE1/2-K-Mediated Drug Transport and Intracellular Accumulation.

Authors:  Jia Yin; Haichuan Duan; Joanne Wang
Journal:  J Pharmacol Exp Ther       Date:  2016-10-06       Impact factor: 4.030

7.  Characterization of Meta-Iodobenzylguanidine (mIBG) Transport by Polyspecific Organic Cation Transporters: Implication for mIBG Therapy.

Authors:  Antonio J López Quiñones; David J Wagner; Joanne Wang
Journal:  Mol Pharmacol       Date:  2020-06-02       Impact factor: 4.436

Review 8.  Renal drug transporters and their significance in drug-drug interactions.

Authors:  Jia Yin; Joanne Wang
Journal:  Acta Pharm Sin B       Date:  2016-08-09       Impact factor: 11.413

9.  Combinatorial Pharmacophore Modeling of Multidrug and Toxin Extrusion Transporter 1 Inhibitors: a Theoretical Perspective for Understanding Multiple Inhibitory Mechanisms.

Authors:  Yuan Xu; Xian Liu; Yulan Wang; Nannan Zhou; Jianlong Peng; Likun Gong; Jing Ren; Cheng Luo; Xiaomin Luo; Hualiang Jiang; Kaixian Chen; Mingyue Zheng
Journal:  Sci Rep       Date:  2015-09-02       Impact factor: 4.379

Review 10.  The role of drug transporters in the kidney: lessons from tenofovir.

Authors:  Darren M Moss; Megan Neary; Andrew Owen
Journal:  Front Pharmacol       Date:  2014-11-11       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.